{"nctId":"NCT01249417","briefTitle":"Dysport® Pediatric Lower Limb Spasticity Study","startDateStruct":{"date":"2011-07"},"conditions":["Cerebral Palsy","Muscle Spasticity","Children"],"count":241,"armGroups":[{"label":"Dysport 10 U/Kg","type":"EXPERIMENTAL","interventionNames":["Biological: Botulinum toxin type A"]},{"label":"Dysport 15 U/Kg","type":"EXPERIMENTAL","interventionNames":["Biological: Botulinum toxin type A"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Botulinum toxin type A","otherNames":["AbobotulinumtoxinA (Dysport®)"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Children aged 2 to 17 years with cerebral palsy\n* Equinus foot position\n* Ambulatory\n* Intensity of muscle tone equal to or greater than 2 in affected lower limb, as measured on the Modified Ashworth Scale\n\nExclusion Criteria:\n\n* Fixed contracture\n* Previous phenol, alcohol injection or surgical intervention\n* Other neurological / neuromuscular disorder\n* Severe athetoid or dystonic movements","healthyVolunteers":false,"sex":"ALL","minimumAge":"2 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in MAS Score in the Gastrocnemius-soleus Complex (GSC) at the Ankle Joint of the (Most) Affected Lower Limb","description":"The MAS is a 6-point scale which measures the intensity of muscle tone by measuring the resistance of the muscle to passive lengthening or stretching. Investigator will grade muscle tone in the GSC from 0 (no increase in tone) to 4 (affected parts rigid in flexion or extension).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.86","spread":null},{"groupId":"OG001","value":"-0.97","spread":null},{"groupId":"OG002","value":"-0.48","spread":null}]}]}]},{"type":"SECONDARY","title":"Physician's Global Assessment (PGA) of the Treatment Response.","description":"PGA Scale of the Treatment Response: Global assessment of treatment response assessed by asking the Investigator the following question: \"how would you rate the response to treatment in the subject's lower limb(s) since the last injection?\" Answers will be made on a 9 point rating scale (-4: markedly worse, -3: much worse, -2: worse, -1: slightly worse, 0: no change, +1: slightly improved, +2: improved, +3: much improved, +4: markedly improved).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.54","spread":null},{"groupId":"OG001","value":"1.5","spread":null},{"groupId":"OG002","value":"0.73","spread":null}]}]}]},{"type":"SECONDARY","title":"Goal Attainment Scale (GAS) Score","description":"GAS is a functional scale used to measure progress towards individual therapy goals. Individual goals defined for each subject by the physician, and the child's parents (caregiver) where applicable, prior to treatment. Post-baseline, the GAS for each goal rated using a defined scale (-2: Much less than expected outcome, -1: somewhat less than expected outcome, 0: expected outcome, 1: somewhat more than expected outcome, and 2: Much more than expected outcome).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.53","spread":null},{"groupId":"OG001","value":"50.86","spread":null},{"groupId":"OG002","value":"46.21","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":80},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Cough","Pyrexia","Influenza"]}}}